The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer
Authors:
- Carina StrandCSCarina Strand
- Martin BakMBMartin Bak
- Signe BorgquistSBSigne Borgquist
- Gunilla ChebilGCGunilla Chebil
- Anna-Karin FalckAFAnna-Karin Falck
- Marie-Louise FjällskogMFMarie-Louise Fjällskog
- Dorthe GrabauDGDorthe Grabau
- Ingrid HedenfalkIHIngrid Hedenfalk
- Karin JirströmKJKarin Jirström
- Marie KlintmanMKMarie Klintman
- Per MalmströmPMPer Malmström
- Hans OlssonHOHans Olsson
Open Access
- 14 March 2013
- journal article
- research article
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 1-10
Abstract
The aim was to confirm a previously defined prognostic index, combining a proliferation marker, histological grade, and estrogen receptor (ER) in different subsets of primary N0/N1 chemo-naïve breast cancer patients. In the present study, including 1,854 patients, Ki67 was used in the index (KiGE), since it is the generally accepted proliferation marker in clinical routine. The low KiGE-group was defined as histological grade 1 patients and grade 2 patients which were ER-positive and had low Ki67 expression. All other patients made up the high KiGE-group. The KiGE-index separated patients into two groups with different prognosis. In multivariate analysis, KiGE was significantly associated with disease-free survival, when adjusted for age at diagnosis, tumor size and adjuvant endocrine treatment (hazard ratio: 3.5, 95% confidence interval: 2.6–4.7, P<0.0001). We have confirmed a prognostic index based on a proliferation marker (Ki67), histological grade, and ER for identification of a low-risk group of patients with N0/N1 primary breast cancer. For this low-risk group constituting 57% of the patients, with a five-year distant disease-free survival of 92%, adjuvant chemotherapy will have limited effect and may be avoided.Keywords
This publication has 48 references indexed in Scilit:
- Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancerBreast Cancer Research and Treatment, 2012
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewBreast Cancer Research and Treatment, 2011
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2011
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysisBreast Cancer Research and Treatment, 2007
- Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patientsBritish Journal of Cancer, 2007
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Expression of cyclins E, A, and B, and prognosis in lymph node‐negative breast cancerThe Journal of Pathology, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001